Electromedical Technologies, Inc. (OTCQB: EMED) Positioned For The Future With WellnessPro™Plus And Planned Wellness Pro® Pod With ‘Future-Ready’ FDA-Cleared Device That Treats Chronic And Acute Pain; EMED Addresses Opioid Abuse Market And $151.7 Billion Chronic Pain Market Seen By 2030
Electromedical Technologies, Inc. (OTCQB: EMED) is positioned for the future. The company, recently up listed to the OTCQB market, is fighting opioid abuse with its FDA-cleared WellnessPro™ bioelectronic Transcutaneous Electrical Nerve Stimulation (TENS) device which addresses chronic and acute pain as well. The Company also is partnering with several universities and colleges to study the impact of electro-modulation and bioelectronics on the human body. It is also planning a future launch of its WellnessPro® Pod to its product line. It is laying a foundation for international sales with its recently opened office in Mexico.
The bioelectronic chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: ABT), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).
Electromedical Technologies, Inc. (OTCQB: EMED) Positioned For The Future With WellnessPro™Plus And Planned Welllness Pro® Pod With ‘Future-Ready’ FDA-Cleared Device That Treats Chronic And Acute Pain; EMED Addresses Opioid Abuse Market And $151.7 Billion Chronic Pain Market Seen By 2030
Research firm Prescient & Strategic Intelligence sees the chronic pain treatment market hitting $151.7 Billion by 2030, reflecting a CAGR of 6.5%% during the forecast period from 2020-2030. The pandemic accelerated the opioid epidemic crisis in the research period and Electromedical Technologies, Inc. (OTCQB: EMED) is addressing this matter. The report finds that North America dominates the global chronic pain market.
A Revolution Is Underway To Solve Health Issues
Matthew Wolfson, founder and CEO of Electromedical Technologies, Inc. (OTCQB: EMED), wrote in a letter to Company shareholders, “A revolution is already underway to solve many health issues by tapping into the body’s built-in electrochemical operating system, and Electromedical Technologies is on the frontline in that battle.”
Electromedical Technologies, Inc. (OTCQB: EMED) Positioned For The Future With WellnessPro™Plus And Planned Welllness Pro® Pod With ‘Future-Ready’ FDA-Cleared Device That Treats Chronic And Acute Pain; EMED Addresses Opioid Abuse Market And $151.7 Billion Chronic Pain Market Seen By 2030
Electromedical Technologies, Inc. (OTCQB: EMED) A Commercial Stage Company
The commercial stage Company is marketing a line of FDA cleared devices for the treatment of chronic acute post traumatic and and post-operative, intractable pain relief. At the same time it is collaborating with university to establish a comprehensive research program that defines the effects of electro-modulation on the human body — especially cell signaling and its effects on virus assembly and immune responses. Electromedical Technologies, Inc. (OTCQB: EMED) Positioned For The Future With WellnessPro™Plus And Planned Welllness Pro® Pod With ‘Future-Ready’ FDA-Cleared Device That Treats Chronic And Acute Pain; EMED Addresses Opioid Abuse Market And $151.7 Billion Chronic Pain Market Seen By 2030
During this COVID-19 pandemic, this is vital research into a timely issue. Fo more information about (OTCQB: EMED), go the company website at electromedtech.com
Source: Stock Market Press
Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.
Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.
Contact:
Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com Safe Harbor Statement:
Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.
See Stock Market Press disclaimer: https://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press
